Renal Mechanism of SGLT2 Inhibition

Renal Mechanism of SGLT2 Inhibition
Conditions:   Type 2 Diabetes;   Diabetic Kidney Disease
Interventions:   Drug: canagliflozin;   Drug: Aminohippurate Sodium Inj 20%
Sponsors:   University of Colorado, Denver;   Boston Medical Center;   University of Michigan;   Brigham and Women’s Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments